Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,422JPY
29 Jul 2014
Price Change (% chg)

¥8 (+0.57%)
Prev Close
¥1,414
Open
¥1,414
Day's High
¥1,428
Day's Low
¥1,409
Volume
4,726,500
Avg. Vol
6,732,556
52-wk High
¥1,428
52-wk Low
¥945

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.63
Market Cap (Mil.): ¥3,196,520.00
Shares Outstanding (Mil.): 2,259.82
Dividend: 14.00
Yield (%): 1.91

Financials

  4503.T Industry Sector
P/E (TTM): 35.02 35.65 36.07
EPS (TTM): 40.39 -- --
ROI: 7.12 18.91 18.18
ROE: 7.44 19.67 19.05
Search Stocks

Aveo, Astellas end pact to develop cancer drug tivozanib

- Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

14 Feb 2014

UPDATE 1-Aveo, Astellas end pact to develop cancer drug tivozanib

Feb 14 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

14 Feb 2014

Aveo, Astellas end pact to develop cancer drug Tivozanib

Feb 14 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug and said they would discontinue a mid-stage study testing its use in colon cancer.

14 Feb 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: MarketLine (a Datamonitor Company)
£114.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks